title: Potentially preventable strokes in high-risk patients with atrial fibrillation who are not adequately anticoagulated.
abstract: OBJECTIVE
  Warfarin is the most effective stroke prevention medication for high-risk individuals with atrial fibrillation, yet it is often underused. This study examined the magnitude of this problem in a large contemporary, prospective stroke registry.
  
  
  METHODS
  We analyzed data from the Registry of the Canadian Stroke Network, a prospective database of consecutive patients with stroke admitted to 12 designated stroke centers in Ontario (2003 to 2007). We included patients admitted with an acute ischemic stroke who (1) had a known history of atrial fibrillation; (2) were classified as high risk for systemic emboli according to published guidelines; and (3) had no known contraindications to anticoagulation. Primary end points were the use of prestroke antithrombotic medications and admission international normalized ratio.
  
  
  RESULTS
  Among patients admitted with a first ischemic stroke who had known atrial fibrillation (n=597), strokes were disabling in 60% and fatal in 20%. Preadmission medications were warfarin (40%), antiplatelet therapy (30%), and no antithrombotics (29%). Of those taking warfarin, three fourths had a subtherapeutic international normalized ratio (<2.0) at the time of stroke admission. Overall, only 10% of patients with acute stroke with known atrial fibrillation were therapeutically anticoagulated (international normalized ratio >/=2.0) at admission. In stroke patients with a history of atrial fibrillation and a previous transient ischemic attack or ischemic stroke (n=323), only 18% were taking warfarin with therapeutic international normalized ratio at the time of admission for stroke, 39% were taking warfarin with subtherapeutic international normalized ratio, and 15% were on no antithrombotic therapy.
  
  
  CONCLUSIONS
  In high-risk patients with atrial fibrillation admitted with a stroke, and who were candidates for anticoagulation, most were either not taking warfarin or were subtherapeutic at the time of ischemic stroke. Many were on no antithrombotic therapy. These findings should encourage greater efforts to prescribe and monitor appropriate antithrombotic therapy to prevent stroke in individuals with atrial fibrillation.
authors.affiliation: FRCPC, Director, Regional Stroke Prevention Clinic, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Room A442, Toronto, Ontario, Canada. david.gladstone@sunnybrook.ca
authors.forename: David J
authors.initials: DJ
authors.lastname: Gladstone
authors.forename: Esther
authors.initials: E
authors.lastname: Bui
authors.forename: Jiming
authors.initials: J
authors.lastname: Fang
authors.forename: Andreas
authors.initials: A
authors.lastname: Laupacis
authors.forename: M Patrice
authors.initials: MP
authors.lastname: Lindsay
authors.forename: Jack V
authors.initials: JV
authors.lastname: Tu
authors.forename: Frank L
authors.initials: FL
authors.lastname: Silver
authors.forename: Moira K
authors.initials: MK
authors.lastname: Kapral